225 related articles for article (PubMed ID: 26202186)
1. Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function.
Hirota SA
Mini Rev Med Chem; 2015; 16(3):206-17. PubMed ID: 26202186
[TBL] [Abstract][Full Text] [Related]
2. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
3. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
4. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
6. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
8. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.
Bajaj JS; Barbara G; DuPont HL; Mearin F; Gasbarrini A; Tack J
Dig Liver Dis; 2018 Aug; 50(8):741-749. PubMed ID: 29807873
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
[TBL] [Abstract][Full Text] [Related]
10. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
11. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin is a gut-specific human pregnane X receptor activator.
Ma X; Shah YM; Guo GL; Wang T; Krausz KW; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2007 Jul; 322(1):391-8. PubMed ID: 17442842
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.
Koo HL; DuPont HL
Curr Opin Gastroenterol; 2010 Jan; 26(1):17-25. PubMed ID: 19881343
[TBL] [Abstract][Full Text] [Related]
17. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
19. Pregnane X receptor as a target for treatment of inflammatory bowel disorders.
Cheng J; Shah YM; Gonzalez FJ
Trends Pharmacol Sci; 2012 Jun; 33(6):323-30. PubMed ID: 22609277
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids.
de Wit K; Beuers U; Mukha A; Stigter ECA; Gulersonmez MC; Ramos Pittol JM; Middendorp S; Takkenberg RB; van Mil SWC
Liver Int; 2023 Mar; 43(3):649-659. PubMed ID: 36463417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]